文献速递胸部肿瘤乳腺癌消化系统肿瘤

血浆游离DNA靶向甲基化测序用于癌症检测与分类

Targeted methylation sequencing of plasma cell-free DNA for cancer detection and classification.
PubMed 文献 · Ann Oncol · 2018-01-01

本研究开发了靶向9223个CpG位点的甲基化测序方法,并用78例晚期结直肠癌、非小细胞肺癌、乳腺癌或黑色素瘤患者的血浆cfDNA进行临床验证。结果显示,治疗中患者的甲基化评分低于未治疗者,未治疗者中甲基化评分可检测83.8%的癌症存在,并准确分类78.9%的癌症类型;低甲基化评分与更长生存期和治疗失败时间相关。

要点

  • 靶向9223个CpG位点的血浆cfDNA甲基化测序可检测晚期常见癌症并分类。
  • 未治疗患者中甲基化评分检测癌症的敏感性为83.8%,分类准确率78.9%。
  • 低甲基化评分与更长生存期和治疗失败时间相关。

核心结论

  • 靶向9223个CpG位点的血浆cfDNA甲基化测序可高精度检测常见晚期癌症的存在及类型。
  • 血浆cfDNA甲基化评分与治疗结局相关。

研究设计与样本

  • 开发靶向9223个CpG位点的综合甲基化测序方法,位点基于癌症基因组图谱(TCGA)中一致高甲基化的位点。
  • 使用78例晚期结直肠癌、非小细胞肺癌(NSCLC)、乳腺癌或黑色素瘤患者的血浆cfDNA样本进行临床验证,并与患者结局比较。

主要发现

  • 治疗中患者血浆cfDNA甲基化评分中位数低于未治疗患者(4.74 vs 85.29;P=0.001)。
  • 68例未治疗患者血浆样本中,甲基化评分检测到57例(83.8%)存在癌症,其中45例(78.9%)基于甲基化特征准确分类了潜在癌症类型。
  • 检测癌症的准确性:结直肠癌96.3%,乳腺癌91.7%,黑色素瘤81.8%,NSCLC 61.1%;分类准确性:结直肠癌88.5%,NSCLC 81.8%,乳腺癌72.7%,黑色素瘤55.6%。
  • 低甲基化评分与高评分相比,与更长生存期(10.4 vs 4.4个月,P<0.001)和更长治疗失败时间(2.8 vs 1.6个月,P=0.016)相关。

临床怎么用

  • 对于晚期常见癌症患者,血浆cfDNA靶向甲基化测序可能辅助检测癌症存在及类型。
  • 甲基化评分可能用于提示治疗结局,低评分与更好生存相关。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Targeted methylation sequencing of plasma cell-free DNA (cfDNA) has a potential to expand liquid biopsies to patients with tumors without detectable oncogenic alterations, which can be potentially useful in early diagnosis. PATIENTS AND METHODS: We developed a comprehensive methylation sequencing assay targeting 9223 CpG sites consistently hypermethylated according to The Cancer Genome Atlas. Next, we carried out a clinical validation of our method using plasma cfDNA samples from 78 patients with advanced colorectal cancer, non-small-cell lung cancer (NSCLC), breast cancer or melanoma and compared results with patients' outcomes. RESULTS: Median methylation scores in plasma cfDNA samples from patients on therapy were lower than from patients off therapy (4.74 versus 85.29; P = 0.001). Of 68 plasma samples from patients off therapy, methylation scores detected the presence of cancer in 57 (83.8%), and methylation-based signatures accurately classified the underlying cancer type in 45 (78.9%) of these. Methylation scores were most accurate in detecting colorectal cancer (96.3%), followed by breast cancer (91.7%), melanoma (81.8%) and NSCLC (61.1%), and most accurate in classifying the underlying cancer type in colorectal cancer (88.5%), followed by NSCLC (81.8%), breast cancer (72.7%) and melanoma (55.6%). Low methylation scores versus high were associated with longer survival (10.4 versus 4.4 months, P < 0.001) and longer time-to-treatment failure (2.8 versus 1.6 months, P = 0.016). CONCLUSIONS: Comprehensive targeted methylation sequencing of 9223 CpG sites in plasma cfDNA from patients with common advanced cancers detects the presence of cancer and underlying cancer type with high accuracy. Methylation scores in plasma cfDNA correspond with treatment outcomes.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Liu L, Toung JM, Jassowicz AF, et al. Targeted methylation sequencing of plasma cell-free DNA for cancer detection and classification. Ann Oncol. 2018. PMID: 29635542. doi:10.1093/annonc/mdy119

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。